106 related articles for article (PubMed ID: 19804127)
1. Tirofiban: a critical reappraisal of the clinical use, recent developments and future perspectives.
Valgimigli M; Campo G; Percoco G; Pellegrino L; Guardigli G; Ferrari R
Future Cardiol; 2006 Jan; 2(1):17-27. PubMed ID: 19804127
[TBL] [Abstract][Full Text] [Related]
2. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Alexander JH; Harrington RA
Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
[TBL] [Abstract][Full Text] [Related]
3. Current strategies with high-dose tirofiban.
Mukherjee D; Roffi M
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):275-80. PubMed ID: 17428156
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
[TBL] [Abstract][Full Text] [Related]
5. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
Moliterno DJ;
Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP
Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
Ibbotson T; McGavin JK; Goa KL
Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
9. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Cohen M
J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab.
Kondo K; Umemura K
Clin Pharmacokinet; 2002; 41(3):187-95. PubMed ID: 11929319
[TBL] [Abstract][Full Text] [Related]
11. Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty.
Bilsel T; Akbulut T; Yesilcimen K; Terzi S; Sayar N; Dayi SU; Akgoz H; Ergelen M; Ciloglu F
Heart Vessels; 2006 Mar; 21(2):102-7. PubMed ID: 16550311
[TBL] [Abstract][Full Text] [Related]
12. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).
Huynh T; Theroux P; Snapinn S; Wan Y;
Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321
[TBL] [Abstract][Full Text] [Related]
13. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
Galli M; Maggioni AP; Vassanelli C; Tavazzi L
Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
[TBL] [Abstract][Full Text] [Related]
14. Tirofiban: an investigational platelet glycoprotein IIb/IIIa receptor antagonist.
Kumar A; Herrmann HC
Expert Opin Investig Drugs; 1997 Sep; 6(9):1257-67. PubMed ID: 15991900
[TBL] [Abstract][Full Text] [Related]
15. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
Valgimigli M; Tebaldi M; Campo G; Gambetti S; Bristot L; Monti M; Parrinello G; Ferrari R;
JACC Cardiovasc Interv; 2012 Mar; 5(3):268-77. PubMed ID: 22440491
[TBL] [Abstract][Full Text] [Related]
16. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
Ibbotson T; McGavin JK; Goa KL
Drugs; 2003; 63(11):1121-63. PubMed ID: 12749745
[TBL] [Abstract][Full Text] [Related]
17. Tirofiban. A review of its use in acute coronary syndromes.
McClellan KJ; Goa KL
Drugs; 1998 Dec; 56(6):1067-80. PubMed ID: 9878994
[TBL] [Abstract][Full Text] [Related]
18. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
Cohen M
Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103
[TBL] [Abstract][Full Text] [Related]
20. Downstream administration of a high-dose tirofiban bolus in high-risk patients with unstable angina undergoing early percutaneous coronary intervention.
Danzi GB; Sesana M; Capuano C; Mauri L; Predolini S; Baglini R
Int J Cardiol; 2006 Feb; 107(2):241-6. PubMed ID: 16412804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
